Clinical Trial Update: Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302 [Phase 3]

View source ↗

Summary

A Phase 3 follow-up study evaluated the safety of enteric-coated mycophenolate sodium in renal transplant patients who completed the prior CERL080A302 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: Novartis | Conditions: Renal Transplant | Phase 3 | Status: COMPLETED